Contents

Effect of Corneal Cross-linking versus Standard Care on Keratoconus Progression in Young Patients (KERALINK)

November 1, 2021

Clinical Trial

Effect of Corneal Cross-linking versus Standard Care on Keratoconus Progression in Young Patients: The KERALINK Randomized Controlled Trial.

Larkin DFP, Chowdhury K, Burr JM, Raynor M, Edwards M, Tuft SJ, Bunce C, Caverly E, Doré C; KERALINK Trial Study Group.

Ophthalmology. 2021 Nov;128(11):1516-1526.
Full text | Metrics.

Main finding: CXL arrests progression of keratoconus in the majority of young patients. CXL should be considered as a first-line treatment in progressive disease.

 

  • Purpose: To examine the efficacy and safety of corneal cross-linking (CXL) for stabilization of progressive keratoconus.
  • Study type: Randomized controlled Trial
  • Condition: Keratoconus

Participants: 10-16yo, progressive keratoconus

 

  • n=60

 

Intervention:

 

Group 1: corneal cross-linking (CXL) + standard of care
Group 2: Standard of care

The unadjusted odds ratio suggests that on average, patients in the CXL arm had 90% lower odds of experiencing progression compared with those receiving standard care.

CXL Standard care
Mean K2 at 18 months 49.7D 53.4D
Keratoconus progression 7% 43%

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed